Standard BioTools

Overview

Standard BioTools, founded in 1999 and headquartered in the United States, operates within the manufacturing sector, specifically focusing on medical devices and equipment, nanotechnology, and clinical laboratory services. The company employs between 501 and 1,000 individuals and reported revenue of approximately $169.7 million. Standard BioTools is engaged in the development of innovative solutions for the healthcare and biotechnology industries, with a particular emphasis on blood-based biomarkers for neurological disorders. Their recent white paper discusses the advantages of using blood-based biomarkers (BBBs) for early detection, monitoring, and patient stratification in neurological diseases, highlighting their minimally invasive nature and cost-effectiveness compared to traditional methods. The document also describes advanced technologies such as the SomaScan™ assay for protein profiling, KREX™ microarrays for antibody profiling, and CyTOF™ technology for single-cell proteomics, which are utilized to analyze various biological fluids and enhance understanding of neurological conditions. This focus on research and technology positions Standard BioTools as a contributor to advancements in clinical diagnostics and therapeutic strategies in the medical field.

Industry